Alaunos: Early Clinical Data Shows Objective Clinical Response Using its TCR-T Cell Therapy

 

• First patient dosed achieved a confirmed objective partial response

• Second patient dosed at second dose level; cleared 28-day safety window
• Data to be presented on Friday, September 30 at 8:30am ET in a proffered presentation at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON)

https://www.biospace.com/article/releases/alaunos-therapeutics-announces-early-clinical-data-showing-objective-clinical-response-using-its-tcr-t-cell-therapy/